Clinical trials
Urinary Bladder, Overactive trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Terminated | 7 |
| Recruiting | 2 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Allergan | 8 |
| Astellas Pharma Inc | 8 |
| Astellas Pharma Europe B.V. | 6 |
| Pfizer | 5 |
| Astellas Pharma Europe Ltd. | 3 |
| MedtronicNeuro | 3 |
| Astellas Pharma Global Development, Inc. | 2 |
| Axonics, Inc. | 2 |
| Ipsen | 2 |
| Avera Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Bladder, Overactive | 54 |
| Urinary Incontinence | 17 |
| Urinary Incontinence, Urge | 10 |
| Lower Urinary Tract Symptoms | 4 |
| Urinary Bladder Diseases | 4 |
| Urologic Diseases | 4 |
| Multiple Sclerosis | 2 |
| Nocturia | 2 |
| Urinary Incontinence, Stress | 2 |
| Anxiety Disorders | 1 |
Trials
Showing 1 to 25 of 54. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.